Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

Journal:
The Lancet Oncology
Published:
DOI:
10.1016/s1470-2045(26)00014-8
Affiliations:
11
Authors:
12
Go to article
Institutions Authors Share
Bayer U.S., United States of America (USA)
2.000000
 0.17
Dana-Farber Cancer Institute (DFCI), United States of America (USA)
1.000000
 0.08
All India Institute of Medical Sciences - New Delhi (AIIMS New Delhi), India
1.000000
 0.08
Lithuanian University of Health Sciences (LSMU), Lithuania
1.000000
 0.08
Instituto de Investigación Hospital 12 de Octubre (i+12), Spain
1.000000
 0.08
START Carolinas, United States of America (USA)
1.000000
 0.08
Pauls Stradins Clinical University Hospital, Latvia
1.000000
 0.08
Cancer Institute and Hospital, CAMS & PUMC, China
1.000000
 0.08
Bayer Ireland, Ireland
1.000000
 0.08
Bayer Consumer Care AG, Switzerland
1.000000
 0.08
Hospital of the University of Montreal (CHUM), Canada
1.000000
 0.08
Interested in Oncology and Carcinogenesis?